Unknown

Dataset Information

0

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.


ABSTRACT: BACKGROUND:Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs) of patients with genotype 2 and 3 has not been described. METHODS:PROs data were collected from participants of ASTRAL-2 and ASTRAL-3 studies before, during, and after treatment using 4 PRO instruments (Short Form-36, Chronic Liver Disease Questionnaire-HCV, Functional Assessment of Chronic Illness Therapy-Fatigue, and Work Productivity and Activity Index: Specific Health Problem), and compared between the SOF/VEL and SOF + RBV groups. RESULTS:A total of 818 HCV patients were included: 78% treatment naive, 25% cirrhosis. The rates of nearly all adverse events were lower in the RBV-free SOF/VEL group (all P < .03). The SOF/VEL group also experienced improvement of their PROs by treatment week 4 (+1.8% on average across all PROs), which continued throughout treatment (+4.1%) and post-treatment (+5.5%). In contrast, those in the SOF + RBV group had a modest decline in their PROs starting at treatment week 4 (up to -3.7%), which lasted until the end of treatment (up to -6.4%). In multiple regression analysis, the association of a treatment regimen with end-of-treatment PROs was significant for nearly all PROs; the average beta was +5.0% for the use of SOF/VEL (reference: SOF + RBV). CONCLUSIONS:Patients receiving ribavirin-free SOF/VEL reported significantly better PRO scores during treatment compared with those receiving the RBV-containing regimen. Furthermore, the interferon- and ribavirin-free SOF/VEL regimen resulted in a rapid improvement of PROs in HCV GTs 2 and 3 patients during treatment and after achieving sustained virologic response.

SUBMITTER: Younossi ZM 

PROVIDER: S-EPMC6276885 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

Younossi Zobair M ZM   Stepanova Maria M   Sulkowski Mark M   Foster Graham R GR   Reau Nancy N   Mangia Alessandra A   Patel Keyur K   Bräu Norbert N   Roberts Stuart K SK   Afdhal Nezam N   Nader Fatema F   Henry Linda L   Hunt Sharon S  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20160720 8


<h4>Background</h4>Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes (PROs) of patients with genotype 2 and 3 has not been described.<h4>Methods</h4>PROs data were collected from participants of ASTRAL-2 and ASTRAL-3 studies before, during, and after treatment u  ...[more]

Similar Datasets

| S-EPMC5106608 | biostudies-literature
| S-EPMC6096959 | biostudies-literature
| S-EPMC6502110 | biostudies-literature
| S-EPMC6015630 | biostudies-literature
| S-EPMC8627798 | biostudies-literature
| S-EPMC8297876 | biostudies-literature
| S-EPMC6448908 | biostudies-literature
| S-EPMC5733818 | biostudies-other
| S-EPMC4997358 | biostudies-literature
| S-EPMC5007583 | biostudies-literature